Amgen’s blockbuster hopeful Lumakras sees slower than expected sales in latest data, analyst says

It’s been only about one year since Amgen’s KRAS-targeted NSCLC drug Lumakras has been marketed in the US, and already analysts are warning of waning sales for the blockbuster hopeful.

A report from SVB Securities on Monday said Lumakras’ Q2 sales didn’t come in as high as expected, with the...

Click to view original post